Opinion

Video

ASCO 2024 Updates: Novel Approaches in NSCLC Therapy

Author(s):

Mark A. Socinski, MD,Helena A. Yu, MD

The panel explores promising novel therapies in the treatment landscape, focusing on new or recently presented data at the American Society of Clinical Oncology (ASCO) 2024 annual meeting, and share their insights on the potential impact of these therapies on future clinical practice.

  1. Are there any novel therapies in this treatment space that you find interesting that you would like to discuss that are either new or being presented at ASCO this year?

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona

May 13th 2025 - Jun 18th 2025

online-activity
View More
16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™
Video

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

May 9th 2025 - Jun 14th 2025

online-activity
View More
Proactive Adverse Event Management for HER2+ BTC Treatments
Video

Proactive Adverse Event Management for HER2+ BTC Treatments

May 8th 2025 - May 9th 2026

online-activity
View More
Related Content
Image Credit: © catalin – stock.adobe.com
May 15th 2025

First-Line Eftilagimod Alpha Plus Pembrolizumab/Chemo Yields Responses in Advanced Nonsquamous NSCLC

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

Joshua K. Sabari, MD
May 15th 2025

Lung Cancer Experts Highlight the Most Anticipated Abstracts at the 2025 ASCO Annual Meeting

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

Leptomeningeal Metastases | Image Credit: © Joshua – stock.adobe.com
May 14th 2025

Rhenium (Re186) Obisbemeda Shows Initial Safety, Clinical Benefit in Leptomeningeal Metastases

Image Credit: © catalin – stock.adobe.com
May 13th 2025

Frontline Belrestotug Plus Dostarlimab Misses PFS End Point in PD-L1–High NSCLC